Endocyte

CompanyUnited StatesFounded 1996

Endocyte develops one asset, in phase 1 (EC1456 in ovary cancer). Mostly small molecule acting on FOLR1 and TOP2A; based in the United States, founded in 1996.

1
Asset
Furthest stage: Phase 1; 3
Trials: 0
Signals

Pipeline

1

EC1456
Folate receptor-targeted tubulysin conjugate
Phase 1, Small molecule, FOLR1, TOP2A, ovary cancer

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Trials3
Similar companies6